source
- ADARx prices $446.3 million Nasdaq debut, boosting biotech IPO waveADARx Pharmaceuticals, a RNA interference focused biotech, announced pricing of its initial public offering at $446.3 million on Nasdaq. The offering was upsized, reflecting strong investor demand…
- ADARx upsizes Nasdaq IPO to $446M as City Therapeutics eyes public listingADARx Pharmaceuticals, a San Diego-based RNA biotech, completed a Nasdaq initial public offering this morning, selling 26.3 million shares at $17 each. The offering generated gross proceeds of abo…